Page 32 - Read Online

Page 14 of 18 Padoan et al. Vessel Plus 2021;5:41 https://dx.doi.org/10.20517/2574-1209.2021.41

crucial for readily arriving at the proper diagnosis, which allows the timely initiation of appropriate therapy.
Therefore, AAV patients must be followed up regularly and frequently, in order to detect early relapses and
reduce damage accrual of the affected areas.

DECLARATIONS
Authors’ contributions
Conceptualization: Padoan R, Campaniello D, Felicetti M, Cazzador D, Schiavon F
Investigation: Padoan R, Schiavon F
Writing review: Padoan R, Campaniello D, Felicetti M, Cazzador D, Schiavon F
Editing: Padoan R, Cazzador D, Schiavon F
Drafting and revising figures: Padoan R, Cazzador D
Supervision of ENT surgery topics: Cazzador D, Schiavon F

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of
antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Arthritis Rheum 2012;64:3452-62. DOI PubMed PMC
2. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis.
Summary. Arthritis Rheum 1990;33:1135-6. DOI PubMed
3. Kallenberg CGM. Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Curr
Opin Rheumatol 2016;28:8-14. DOI PubMed
4. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-
23. DOI PubMed PMC
5. Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.
Neurology 2020;94:E1726-37. DOI PubMed
6. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis:
Does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934-9. DOI PubMed
7. Felicetti M, Cazzador D, Padoan R, et al. Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and
how it determines disease severity and long-term outcomes. Clin Rheumatol 2018;37:1075-83. DOI PubMed
8. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel
vasculitis. Ann Rheum Dis 2009;68:310-7. DOI PubMed
9. Yates M, Watts R. ANCA-associated vasculitis. Clin Med 2017;17:60-4. DOI PubMed PMC
10. Nishi R, Koike H, Ohyama K, et al. Association between IL-5 levels and the clinicopathologic features of eosinophilic
granulomatosis with polyangiitis. Neurology 2021;96:226-9. DOI PubMed
11. Bligny D, Mahr A, Toumelin P Le, et al. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93
patients. Arthritis Rheum 2004;51:83-91. DOI PubMed